In light of these findings, combining SHP2 and KRAS G12C inhibitors offers a promising approach for treating KRAS-mutant tumors by reshaping the tumor’s immune landscape to counter resistance mechanisms [133]. This evidence concerns the gene PTPN11 and neoplasm.